ORGOVYX

This brand name is authorized in Austria, Estonia, Spain, France, Croatia, Ireland, Italy, Lithuania, Romania, United States

Active ingredients

The drug ORGOVYX contains one active pharmaceutical ingredient (API):

1 Relugolix UNII P76B05O5V6 - RELUGOLIX

Relugolix is a nonpeptide GnRH receptor antagonist that competitively binds to GnRH receptors in the anterior pituitary gland preventing native GnRH from binding and signalling the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Consequently, the production of testosterone from the testes is reduced. Read about Relugolix

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ORGOVYX Film-coated tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR
ORGOVYX Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L02BX04		L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02B Hormone antagonists and related agents → L02BX Other hormone antagonists and related agents
Discover more medicines within L02BX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1883134
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1221642001
Country: FR	Base de données publique des médicaments	Identifier(s): 65083759
Country: IT	Agenzia del Farmaco	Identifier(s): 050079019, 050079021
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1094667, 1096914
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W69487001
Country: US	FDA, National Drug Code	Identifier(s): 72974-120